News - Global, Bristol-Myers Squibb

Filter

Popular Filters

Bayer/Janssen's Xarelto poised to lead sales in VTE market: report

30-08-2013

German drug major Bayer (BAYN: DE) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Xarelto (rivaroxaban)…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJanssenJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27-08-2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

B-MS' nivolumab to lead NSCLC market with sales of $1.75 billion by 2022, says GlobalData

08-07-2013

US pharma major Bristol-Myers Squibb's (NYSE: BMY) nivolumab will overtake proven blockbuster competitors…

Bristol-Myers SquibbGlobalMarkets & MarketingnivolumabOncologyPharmaceutical

Prognosis for renal cell carcinoma market development

27-11-2012

Through 2021, small-molecule angiogenesis inhibitors will dominate the renal cell carcinoma (RCC) drug…

Bristol-Myers SquibbGlaxoSmithKlineGlobalMarkets & MarketingnivolumabOncologyPfizerPharmaceuticalSutentVotrient

Use of low-molecular-weight heparins and vitamin K antagonists for VTE set for sharp decline as oral agents roll out

21-11-2012

The market shares of low-molecular-weight heparins and vitamin K antagonists continue to be gradually…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalMarkets & MarketingPfizerPharmaceuticalXarelto

Atrial fibrillation drug market will grow from $2.7 billion in 2011 to $9.2 billion in 2021

13-11-2012

The atrial fibrillation drug market will experience dramatic growth over the next decade, increasing…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report

18-09-2012

The launches of Bristol-Myers Squibb's (NYSE: BMY) immunotherapy Yervoy (ipilimumab) and Roche (ROG:…

Bristol-Myers SquibbdabrafenibGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRochetrametinibYervoyZelboraf

Back to top